Published:
Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
ANN ARBOR, Mich., July 18 /PRNewswire/ -- Velcura Therapeutics, Inc. CEO
Michael Long, Ph.D., announced that William F. Brinkerhoff has joined the
Board of Directors of the biotechnology company, which completed a
first-in-man clinical trial for VEL-0230, a powerful anti-inflammatory agent
stimulating bone formation and inhibiting bone loss. Velcura is investigating
its lead compound as a treatment for rheumatoid arthritis and other bone
diseases.
Bill Brinkerhoff is the chief operating officer of Cerenis Therapeutics,
which is focused on the discovery, development and commercialization of
breakthrough HDL-related therapies for the treatment of cardiovascular and
metabolic diseases.
"In joining Velcura's Board, I look forward to assisting them in their
mission of developing therapies that restore bone health," said Bill
Brinkerhoff.
Before founding Cerenis in 2005, Brinkerhoff was vice president of
business development for Esperion Therapeutics inAnn Arbor, where he
successfully negotiated multiple large potential partnering agreements prior
to Esperion's acquisition by Pfizer. Before joining Esperion in 2002, he was
the director of business development and director of market planning and sales
operations, for Sankyo Parke Davis inParsippany, New Jersey.
A graduate of the University of Michigan, Brinkerhoff earned his Master of
Business Administration with Distinction in 1989. He also has bachelor's and
master's degrees in Industrial Engineering and Operations Research from U-M's
College of Engineering.
Velcura's other directors are Michael W. Long and Bill Orobone, CEO of
Syneptics, an alternative energy financing entity.
About Velcura Therapeutics, Inc.
Velcura Therapeutics, Inc. is an early stage biotechnology company
headquartered inAnn Arbor, Michigan. Velcura's research focus is to
understand human bone disease and to discover novel therapeutics that restore
bone health. Velcura develops highly differentiated therapies for bone
disease; specifically, therapies that restore the balance between bone
building and bone loss activities in a single molecule. Velcura uses its
patented platform technologies to discover and optimize these compounds. More
information is at www.velcura.com .
Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
Michael W. Long, Ph.D.
http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215
SOURCE Velcura Therapeutics, Inc.
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: Pharmaceuticals, Healthcare, Biotechnology, , michigan
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
